GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mezzion Pharma Co (XKRX:140410) » Definitions » Research & Development

Mezzion Pharma Co (XKRX:140410) Research & Development : ₩411 Mil (TTM As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Mezzion Pharma Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Mezzion Pharma Co's Research & Development for the three months ended in Sep. 2024 was ₩-1,506 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was ₩411 Mil.

Mezzion Pharma Co Research & Development Historical Data

The historical data trend for Mezzion Pharma Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mezzion Pharma Co Research & Development Chart

Mezzion Pharma Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12,149.38 937.56 1,956.03 2,217.03 938.97

Mezzion Pharma Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 237.65 331.01 - 1,586.91 -1,506.49

Mezzion Pharma Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩411 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mezzion Pharma Co  (XKRX:140410) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Mezzion Pharma Co Research & Development Related Terms

Thank you for viewing the detailed overview of Mezzion Pharma Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Mezzion Pharma Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mezzion Pharma Co (XKRX:140410) » Definitions » Research & Development
Comparable Companies
XKRX:039200 XKRX:307750 XKRX:004720 XKRX:014570 XKRX:200780 XKRX:118000 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD LSE:GSK TSE:4568
Traded in Other Exchanges
N/A
Address
C&H, Samseong-dong, 154-8, Gangnam-gu, Dongdaemun-gu, Seoul, KOR, 135-879
Website
http://www.mezzion.co.kr
Mezzion Pharma Co is a South Korea based drug manufacturer company. It develops and manufactures pharmaceutical products for erectile dysfunction and benign prostatic hyperplasia.

Mezzion Pharma Co Headlines

No Headlines